Target Claudin 18.2! Tian guangshi biological anti-tumor class 1 new drugs were approved clinically

Screenshot Source: CDE website Claudin protein closely connected molecules, its function is mainly to regulate the permeability of the barrier structure.
Claudin 18.2 is a member of the Claudin protein family, a highly tissue-specific protein expressed only in epithertic cells that have differentiated on the mucous membranes of the stomach under normal physiological conditions.
, the study found that Claudin 18.2 showed high expression in many primary and post-metastatic cancer types.
, for example, have Claudin 18.2 protein in 50 to 80 percent of gastric cancer patients.
, Claudin 18.2 also has activation expression in tumors such as pancreatic, esophageal, and ovarian cancers.
, the Claudin 18.2 protein became an effective target for researchers to develop immunotherapy for solid tumors such as stomach and pancreatic cancer.
MIL93 is an innovative Claudin 18.2 monoclonal antibody independently developed by Tianguang Bio based on its glyco-based modified antibody technology platform, which can kill tumors through antibody-induced cytotoxic action (ADCC) and antibody-induced complement killing effect (CDC), and is intended to be developed for the treatment of Claudin 18.2 positive gastric cancer/gastroesophageal binding and pancreatic cancer.
According to Tianguang Biological's prospectus, MIL93's new binding table allows antibodies to bind more steadily to tumor cells, and glycosylation modifications make the drug candidate have stronger ADC and CDC effects, resulting in better anti-tumor effects.
This approved clinical trial is a Phase 1 clinical study designed to evaluate the tolerance and safety of MIL93 in patients with localized late stage or metastasis solid tumors and to determine dose-limiting toxicity and maximum to-to-dosage, pharmacogenetic characteristics, immunogenicity, and initial clinical efficacy.
patients are targeted for recurring recurring recurring refraped or metastasis solid tumors that are ineffective for standard treatment, cannot be treated with standard treatment, or are not treated with standard treatment.
founded in 2003, Tianguangshi Bio is an innovative biopharmaceutical company focused on drug research and development in the fields of oncology, autoimmune diseases, cardiovascular diseases and other diseases.
, the company has seven core products (covering nine clinical studies) that have entered the clinical stage or applied for IND.
addition, there are more than ten varieties in the preclinical research and development stage.
the end of September this year, the company has submitted an IPO application to the SSE.
Tianguangshi Bio-Core Product Pipeline (Screenshot Source: Reference: References) References: s1. CDE.Retrieved Oct 22, 2020, from Beijing Tianguangshi Biotechnology Co., Ltd. Prospectus. Retrieved Sep 28, 2020, from Source: Medical Mission Hills